Keyword: Turku Bioscience Centre
Turku Bioscience Centre, or Turku Bioscience in short, a joint unit of the University of Turku and Åbo Akademi University offering technology services and producing top research in biosciences is celebrating its 30th anniversary this year. On Wednesday 2 October, the Centre celebrated this with a seminar showcasing its achievements throughout the years.
Jane and Aatos Erkko Foundation has awarded 1.7 million euros for T-cell research that is led by academy professor Riitta Lahesmaa.
Corporate Corner promotes academia-to-business collaboration and co-creation. We help academic and industrial researchers to create new ideas and products and solve existing problems within research and development. Corporate corner brings partners together to discuss, develop and co-invent within various fields of science. Through shared ideas and know-how, resources and infrastructures, Corporate Corner fuels new opportunities and supports societal well-being and economic growth.
Connect to co-create!
Researchers from the Turku Bioscience Centre have found changes in molecules in the blood that might be new markers of type 1 diabetes. The new findings may help understand the early pathogenesis of the disease.
Open Access Technology Centres Transform the Way Research Is Conducted — Turku Bioscience Operates at the Frontiers of Science
Among all the branches of life sciences, cell and molecular biology have often relied upon the development of key enabling technologies. Several significant paradigm shifts in biosciences have their origins specifically in novel and innovative technologies and/or methods.
Using cutting-edge genomics methods a gene signature predicting type 1 diabetes was discovered. This signature is detectable already before the appearance of type 1 diabetes associated autoantibodies. The finding could help in identifying early on the children who are likely to develop the disease later.
Researchers from Turku Bioscience Centre Identified Novel Oncogenic Function for Receptor Linked with Alzheimer’s Disease
Common and rare SORLA single nucleotide polymorphisms have been associated with the development of Alzheimer’s disease. So far, SORLA has been mainly studied in neurons, but the new study focused on the role of SORLA in cancer cells. Led by Academy Professor Johanna Ivaska, the research group observed that SORLA was highly expressed in HER2 positive cancers. Removing SORLA from cancer cells severely impaired the oncogenic fitness of HER2 positive cancers.